Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Leukemia|April 21, 2023
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Loïc Vasseur, Rathana Kim, et al.
Blood Advances|April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trialMarina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Blood|November 3, 2007
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA resultsLionel Adès, Miguel A Sanz, Sylvie Chevret, et al.
Pageof 15